Filing Analysis
OraSure Technologies, Inc. filed an 8-K to announce its consolidated financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal mechanism to furnish quarterly earnings information via a press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Filing date: August 5, 2026.
- The company issued a press release (Exhibit 99.1) containing consolidated financial results.
- CEO Carrie Eglinton Manner signed the report.
OraSure Technologies announced that the FDA has cleared the Colli-Pee™ Dx Urine Collection Kit, produced by its subsidiary DNA Genotek Inc. The kit is designed for at-home self-collection of urine samples to be used with Roche Molecular Systems' diagnostic tests for several sexually transmitted infections.
📋 Key Facts
- FDA clearance granted on June 11, 2026.
- Product: Colli-Pee™ Dx Urine Collection Kit from subsidiary DNA Genotek Inc.
- Compatibility: Works with Roche cobas® 5800, 6800, and 8800 molecular diagnostic systems.
- Targeted Pathogens: Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium.
- Functionality: Supports at-home self-collection of first-void urine for both male and female patients.
OraSure Technologies reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Key approvals include an increase in shares for the Stock Award Plan and a transition to a declassified board of directors.
📋 Key Facts
- Stockholders approved increasing the 2000 Stock Award Plan by 5,000,000 shares of common stock.
- Approved an amendment to the Certificate of Incorporation to declassify the Board of Directors over a three-year period starting at the fiscal 2027 annual meeting.
- Ratified Grant Thornton LLP as the independent registered public accounting firm for fiscal year 2026.
- Elected three Class II Directors: John D. Bertrand, Steven K. Boyd, and Robert W. McMahon.
- Approved a non-binding advisory vote on executive compensation.
OraSure Technologies announced its consolidated financial results for the first quarter ended March 31, 2026. The filing includes a press release and an updated investor presentation used during a management webcast.
📋 Key Facts
- Reported financial results for the quarter ended March 31, 2026.
- Management team, including CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath, held a webcast conference call on May 6, 2026.
- Furnished Exhibit 99.1 (Press Release) and Exhibit 99.2 (Investor Presentation).
- The filing was made under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
OraSure Technologies entered into a cooperation agreement with activist investor Altai Capital Management to resolve a potential proxy contest. The agreement includes the appointment of a new director, a commitment to declassify the board, and a standstill agreement from the investor.
🚩 Red Flags
- The agreement stems from activist investor pressure and a prior notice of nominations/proposals from Altai Capital.
- The Board's flexibility is restricted by a cap on the number of directors (8) until 2027.
📋 Key Facts
- Appointed John D. Bertrand as a Class II director and member of the Nominating and Corporate Governance Committee, effective April 16, 2026.
- Altai Capital Management agreed to withdraw its prior director nominations and stockholder proposals.
- The Company committed to seeking stockholder approval at the 2026 Annual Meeting to declassify the Board, phasing in annual director elections.
- The Board size is capped at eight directors until the 2027 annual meeting without Altai's consent.
- Mr. Bertrand received an initial equity award of $100,000 in restricted stock vesting over two years.
- Altai is required to vote in accordance with the Board's recommendations, with limited exceptions for ISS/Glass Lewis recommendations or extraordinary transactions.
OraSure Technologies issued an investor presentation on March 30, 2026, addressing company performance and governance in response to statements from Altai Capital Management. This filing indicates an active engagement or conflict with an activist investor.
🚩 Red Flags
- Activist investor pressure from Altai Capital Management regarding governance and performance.
- Potential proxy contest indicated by the Rule 14a-12 check box.
📋 Key Facts
- The filing was made under Item 7.01 (Regulation FD Disclosure) on March 30, 2026.
- The company released an investor presentation (Exhibit 99.1) regarding performance and governance.
- The presentation is a direct response to recent statements made by Altai Capital Management.
- The filing includes soliciting material pursuant to Rule 14a-12, suggesting a potential proxy contest or shareholder vote.
Dr. David J. Shulkin notified OraSure Technologies of his resignation from the Board of Directors and the Compensation Committee, effective March 2, 2026. The company confirmed that the departure was not due to any disagreement with management or the board.
📋 Key Facts
- Resignation notification date: February 28, 2026
- Effective date of resignation: March 2, 2026
- Director: David J. Shulkin, M.D.
- Committee membership: Compensation Committee
- The company explicitly stated there were no disputes or disagreements regarding operations, policies, or practices
OraSure Technologies announced its consolidated financial results for the fourth quarter and full year ended December 31, 2025. The filing includes a press release and an investor presentation used for a management webcast on February 25, 2026.
📋 Key Facts
- Announced Q4 and full-year 2025 financial results on February 25, 2026.
- CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath conducted a webcast for analysts and investors.
- Furnished an updated investor presentation as Exhibit 99.2.
- The filing includes Items 2.02 (Results of Operations) and 7.01 (Regulation FD Disclosure).
OraSure Technologies announced the submission of two separate FDA applications for its rapid molecular self-test for Chlamydia/Gonorrhea (CT/NG) and its Colli-Pee at-home urine collection device. These products are intended for over-the-counter (OTC) use in the STI market.
📋 Key Facts
- Submitted FDA application for a rapid molecular self-test for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG).
- The CT/NG test is designed to provide results in approximately 30 minutes in a disposable format.
- Submitted FDA application for the Colli-Pee at-home urine collection device, intended for multiple STI indications.
- Both products are targeting the over-the-counter (OTC) consumer market.
OraSure Technologies, Inc. announced that its CEO (Carrie Eglinton Manner) and CFO (Kenneth McGrath) have adopted Rule 10b5-1 trading plans for the purchase of company common stock.
📋 Key Facts
- CEO Carrie Eglinton Manner adopted a plan to potentially purchase up to $165,000 of common stock.
- CFO Kenneth McGrath adopted a plan to potentially purchase up to $165,000 of common stock.
- Plans include a cooling-off period (90 days from adoption or 2 business days after the Form 10-K filing, not to exceed 120 days).
- The plans were adopted at a time when officers were not aware of material nonpublic information.
OraSure Technologies, Inc. filed an 8-K to announce its consolidated financial results for the quarter ended September 30, 2025 and provided an investor presentation.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025.
- Filing date: November 5, 2025.
- Management participation: CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath held a webcast to discuss results.
- Exhibits included: Press release (99.1) and Investor Presentation (99.2).
OraSure Technologies announced a leadership transition within its Board of Directors, involving the resignation of Chair Mara G. Aspinall and the appointment of John P. Kenny as the new Chair.
🚩 Red Flags
- None identified; the filing explicitly states the resignation is not due to a disagreement.
📋 Key Facts
- Mara G. Aspinall resigned from her position as Director and Chair of the Board effective October 28, 2025.
- The resignation was not due to any dispute or disagreement with the Company, its management, or the Board.
- John P. Kenny has been appointed as the new Chair of the Board.
- Steven Boyd was appointed as a Class II Director and will serve on the Audit and Nominating/Corporate Governance Committees.
- Steven Boyd received an initial equity award of time-vested restricted shares valued at $100,000, vesting in two years.
OraSure Technologies, Inc. filed an 8-K to announce its consolidated financial results for the quarter ended June 30, 2025 and held a webcast with analysts.
📋 Key Facts
- Reported date: August 5, 2025
- Reporting period: Quarter ended June 30, 2025
- Management participation in webcast included CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath
- The filing includes a press release (Exhibit 99.1) regarding consolidated financial results
OraSure Technologies, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on May 14, 2025. The meeting included the election of three directors and the approval of an amendment to increase authorized shares under the company's Stock Award Plan.
📋 Key Facts
- Stockholders approved an amendment to the OraSure Technologies, Inc. 2000 Stock Award Plan to increase authorized shares by 6,000,000.
- Three Class I Directors were elected: Carrie Eglinton Manner, John P. Kenny, and David J. Shulkin, M.D., with terms ending in 2028.
- Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for Fiscal Year 2025.
- An advisory (non-binding) vote on executive compensation was held.
- As of March 21, 2025, there were 77,488,414 outstanding shares of common stock.
OraSure Technologies, Inc. filed an amendment to its previous 8-K to provide pro forma financial information regarding its acquisition of Sherlock Biosciences, Inc., which closed on December 19, 2024.
🚩 Red Flags
- None identified in this specific amendment; it is a supplemental filing to provide required financial data following an acquisition.
📋 Key Facts
- The filing is Amendment No. 2 to a Form 8-K/A originally filed on December 26, 2024.
- OraSure acquired Sherlock Biosciences, Inc. via a merger agreement effective December 19, 2024.
- The amendment provides unaudited pro forma condensed combined financial information as of January 1, 2024.
- Includes unaudited pro forma condensed combined statements of operations for the year ended December 31, 2024.
OraSure Technologies, Inc. announced the resignation of Kathleen G. Weber from her position as Chief Product Officer, effective June 30, 2025. The departure is classified as a 'Good Reason' resignation under her employment agreement.
🚩 Red Flags
- Departure of a key executive (Chief Product Officer) can signal internal friction or strategic shifts, though 'Good Reason' often implies changes in responsibilities or reporting structures rather than performance issues.
📋 Key Facts
- Kathleen G. Weber is resigning as Chief Product Officer.
- Effective date of resignation: June 30, 2025.
- Resignation is categorized as 'Good Reason' per the Employment Agreement dated January 1, 2019 (as amended).
- Ms. Weber is entitled to severance benefits contingent upon a general release of claims.
OraSure Technologies, Inc. filed an 8-K to announce its consolidated financial results for the fiscal quarter ended March 31, 2025. The company also held a webcast conference call with analysts and investors to discuss these results and other business developments.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Filing date: May 7, 2025
- Management participants in webcast: Carrie Eglinton Manner (President & CEO) and Kenneth J. McGrath (CFO)
- The filing includes a press release as Exhibit 99.1 containing the financial results.
OraSure Technologies, Inc. announced that its Board of Directors approved a new $40 million stock repurchase program on March 21, 2025. This plan will span two years and replaces the previous repurchase program initiated in August 2008.
📋 Key Facts
- Board authorized a stock repurchase program for up to $40 million of common stock on March 21, 2025.
- The new Stock Repurchase Plan has a duration of two years.
- The company is terminating its existing repurchase program that was implemented on August 5, 2008.
- Repurchases will be conducted via open market, private negotiations, or block purchases under Rule 10b-1 and 10b-18.
- The timing and manner of repurchases are at the company's discretion based on market conditions.
OraSure Technologies, Inc. filed an amendment to its December 26, 2024, 8-K to provide required financial statements and pro forma information following the acquisition of Sherlock Biosciences, Inc.
🚩 Red Flags
- Pro forma financial information is for informational purposes only and does not guarantee future results.
📋 Key Facts
- Acquisition of Sherlock Biosciences, Inc. was effective as of December 19, 2024.
- The filing includes audited financial statements for Sherlock for the fiscal year ended Dec 31, 2023, and nine months ended Sept 30, 2024 (Exhibit 99.1).
- Unaudited pro forma condensed combined financial information is provided as of Sept 30, 2024 (Exhibit 99.2).
- The filing serves to satisfy Item 9.01(a) and 9.01(b) requirements regarding business acquisitions.
OraSure Technologies, Inc. issued an 8-K to announce its consolidated financial results for the full year and quarter ended December 31, 2024. The filing includes a press release (Exhibit 99.1) and notes a subsequent webcast with management to discuss business developments.
📋 Key Facts
- Reporting period: Full year and quarter ended December 31, 2024.
- Filing date: February 25, 2025.
- Management participation in webcast included CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath.
- The filing includes Exhibit 99.1 containing the press release of financial results.
OraSure Technologies, Inc. has completed the acquisition of Sherlock Biosciences, Inc. via a merger. The deal includes an upfront payment and contingent milestone/royalty payments based on regulatory approvals and sales.
🚩 Red Flags
- Significant portion of total consideration ($25M+) is contingent on regulatory milestones and future sales performance.
- Complexity in the liquidation waterfall for noteholders, preferred stockholders, and common stockholders.
📋 Key Facts
- Acquisition date: December 19, 2024.
- Upfront consideration: $5 million plus legal expenses and D&O tail insurance costs.
- Milestone payments: Up to $20 million total, contingent on regulatory milestones for Sherlock's CT/NG test.
- Royalties: Mid-single digit percentage of net sales for the CT/NG test through December 31, 2034.
- Structure: Sherlock will operate as a wholly-owned subsidiary of OraSure.
OraSure Technologies, Inc. announced the acquisition of Sherlock Biosciences, Inc. (Sherlock) on December 19, 2024. The company also released an investor presentation to provide further context regarding its strategic direction.
🚩 Red Flags
- Forward-looking statements highlight significant risks regarding the integration of Sherlock's business.
- Risks noted include the ability to achieve anticipated cost savings from restructuring and exiting microbiome services.
- Potential for regulatory delays in obtaining approvals for products in development.
📋 Key Facts
- Acquisition of Sherlock Biosciences, Inc. announced on December 19, 2024.
- Company issued an updated Investor Presentation (Exhibit 99.1).
- The acquisition is part of a broader strategy involving business restructuring and insourcing manufacturing.
OraSure Technologies, Inc. filed an 8-K to announce its consolidated financial results for the quarter ended September 30, 2024 and held a related investor webcast.
📋 Key Facts
- Company announced Q3 2024 financial results on November 6, 2024.
- Management team participation in webcast included CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath.
- The filing includes a press release (Exhibit 99.1) detailing the quarterly performance.
OraSure Technologies, Inc. announced an increase in the size of its Board of Directors from six to seven members. The company appointed John P. Kenny as a new independent director effective September 6, 2024.
📋 Key Facts
- Board size increased from six (6) to seven (7) directors effective September 6, 2024.
- John P. Kenny appointed as Class I Director and member of the Nominating and Corporate Governance Committee.
- Mr. Kenny is deemed independent under Nasdaq rules.
- Initial equity award: $100,000 in time-vested restricted shares, vesting two years from grant date.
- Equity awards include accelerated vesting upon a Change in Control.
OraSure Technologies, Inc. filed an 8-K to announce its consolidated financial results for the second quarter ended June 30, 2024 and held a related investor webcast.
📋 Key Facts
- Report date: August 6, 2024
- Reporting period: Quarter ended June 30, 2024
- Management participants in webcast: Carrie Eglinton Manner (President and CEO) and Kenneth J. McGrath (CFO)
- The filing includes a press release as Exhibit 99.1 regarding financial results.
OraSure Technologies, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on May 14, 2024. Key outcomes included the election of two directors and approval of several shareholder proposals, including an amendment to the stock award plan.
📋 Key Facts
- Stockholders approved an amendment to the 2000 Stock Award Plan to increase authorized shares by 3,000,000.
- Nancy J. Gagliano and Lelio Marmora were elected as Class III Directors for terms ending in 2027.
- Shareholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for Fiscal Year 2024.
- The Company filed a Certificate of Amendment to limit the liability of certain officers, effective May 16, 2024.
- Total outstanding shares at record date (March 22, 2024) were 76,509,975.
OraSure Technologies, Inc. filed an 8-K to announce its consolidated financial results for the fiscal quarter ended March 31, 2024 and held a related investor webcast.
📋 Key Facts
- Announced consolidated financial results for the quarter ending March 31, 2024 via press release (Exhibit 99.1).
- Conducted a webcast conference call on May 8, 2024 with analysts and investors.
- Management participants included Carrie Eglinton Manner (President and CEO) and Kenneth J. McGrath (CFO).
OraSure Technologies reported a cybersecurity incident discovered on March 27, 2024, involving unauthorized access to certain company data. While the company has contained the breach and maintains that core financial systems remain intact, it is still investigating the extent of exfiltrated sensitive information.
🚩 Red Flags
- Data exfiltration confirmed (certain files were exfiltrated).
- Potential for future regulatory and legal notification requirements depending on investigation findings.
- Uncertainty regarding the extent of personal information exposure.
📋 Key Facts
- Cybersecurity incident detected on or about March 27, 2024.
- Unauthorized third party gained access to certain information systems.
- Company has initiated response protocols and engaged cybersecurity experts and external counsel.
- The company believes the incident is contained and core financial/operational systems are secure.
- Investigation is ongoing regarding the extent of exfiltrated sensitive or personal information.
- Management states the incident has not had a material impact on operations or financial condition to date.
OraSure Technologies, Inc. issued an 8-K to announce its consolidated financial results for the full year and quarter ended December 31, 2023. The filing includes a press release (Exhibit 99.1) and notes that management held a webcast to discuss these results.
📋 Key Facts
- Reported consolidated financial results for the full year and quarter ended December 31, 2023.
- Management team, including CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath, participated in an investor webcast on February 27, 2024.
- The filing is a standard earnings release under Items 2.02 and 7.01.
OraSure Technologies announced a strategic investment in KKR Sapphiros, L.P. and entered into a wide-ranging distribution relationship with the entity and its related parties. The company also released an updated investor presentation.
🚩 Red Flags
- Forward-looking statements include significant risks regarding the ability of Sapphiros to obtain regulatory approvals for products in development
- Potential reliance on strategic partners for critical activities under collaborative arrangements
📋 Key Facts
- Investment made in KKR Sapphiros, L.P. ('Sapphiros')
- Entered into a 'wide-ranging' distribution relationship with Sapphiros and certain related entities
- Company issued an updated Investor Presentation (Exhibit 99.1)
- Filing date: January 4, 2024